Research Topics
Species | Allison W KurianSummaryAffiliation: Stanford University Country: USA Publications
| Collaborators
|
Detail Information
Publications
BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implicationsAllison W Kurian
Department of Medicine and Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California 94305 5405, USA
Curr Opin Obstet Gynecol 22:72-8. 2010..To summarize evidence on the prevalence and spectrum of BRCA1 and BRCA2 BRCA1/2 mutations across racial and ethnic groups and discuss implications for clinical practice...
Performance of BRCA1/2 mutation prediction models in Asian AmericansAllison W Kurian
Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305 5405, USA
J Clin Oncol 26:4752-8. 2008..We compared the performance in Asian and white individuals of two widely used BRCA1/2 mutation prediction models, BRCAPRO and Myriad II...
Ductal lavage of fluid-yielding and non-fluid-yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high inherited breast cancer riskAllison W Kurian
Division of Oncology, Department of Medicine, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305 5820
Cancer Epidemiol Biomarkers Prev 14:1082-9. 2005..Most publications on ductal lavage for cell collection report cannulating fluid-yielding ducts only. We report lavage of fluid-yielding and non-fluid-yielding ducts in women at high inherited breast cancer risk...- Opinions of women with high inherited breast cancer risk about prophylactic mastectomy: an initial evaluation from a screening trial including magnetic resonance imaging and ductal lavageAllison W Kurian
Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305 5820, USA
Health Expect 8:221-33. 2005.... - Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groupsAllison W Kurian
Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305 5405, USA
Breast Cancer Res 12:R99. 2010.... - A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancerAllison W Kurian
Department of Medicine, Division of Oncology, and the Veterans Affairs Palo Alto Health Care System and Center for Primary Care and Outcomes Research, Stanford University, Stanford, CA, USA
J Clin Oncol 25:634-41. 2007..We sought to evaluate the cost effectiveness of these regimens, which are expensive and potentially toxic... - Online tool to guide decisions for BRCA1/2 mutation carriersAllison W Kurian
Stanford University School of Medicine, Stanford, CA, USA
J Clin Oncol 30:497-506. 2012..A clinical decision tool could guide these complex choices... - Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinomaAnne-Renee Hartman
Department of Medicine, Stanford University School of Medicine, Stanford, California 94305-5458, USA
Cancer 100:479-89. 2004..A larger screening trial is needed to determine which subgroups of high-risk women will benefit and whether the identification of malignant and high-risk lesions at an early stage will impact breast carcinoma incidence and mortality... - Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriersAllison W Kurian
Departments of Medicine, Health Research and Policy, and Radiology, Stanford University School of Medicine, Stanford, CA, USA
J Clin Oncol 28:222-31. 2010..We used decision analysis to simulate risk-reducing strategies in BRCA1/2 mutation carriers and to compare resulting survival probability and causes of death... - Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imagingSylvia K Plevritis
Department of Radiology, Division of Oncology, Center for Primary Care and Outcomes Research, Stanford University School of Medicine, Stanford, Calif 94305, USA
JAMA 295:2374-84. 2006..Screening with contrast-enhanced breast magnetic resonance imaging (MRI) detects cancer earlier but increases costs and results in more false-positive scans... - A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriersBronislava M Sigal
Department of Radiology, Stanford University School of Medicine, Stanford, CA 94305, USA
Cancer Epidemiol Biomarkers Prev 21:1066-77. 2012..We estimate the impact of different risk-reducing options at various ages on life expectancy... - Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriersAshley D Staton
Department of Medicine, Stanford University School of Medicine, CCSR Building, Room 1115, 269 Campus Drive, Stanford, CA 94305 5151, USA
Fam Cancer 7:179-86. 2008..In order to explore women's preferences for management of elevated cancer risk, we evaluated the decisions of BRCA1/2 mutation carriers about contraception, prophylactic surgery, and family planning... - Ductal pattern enhancement on magnetic resonance imaging of the breast due to ductal lavagePejman Ghanouni
Department of Radiology, Division of Oncology, Stanford University School of Medicine, Stanford, California 94305, USA
Breast J 13:281-6. 2007..Knowledge of the potential for breast MRI enhancement subsequent to DL, which can mimic the appearance of a pathologic lesion, is critical to the care of patients who undergo breast MRI and DL or other intraductal cannulation procedures... - Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutationsMonique A de Bruin
Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
Fam Cancer 11:429-39. 2012..Further investigation of racial differences in BRCA1/2 mutation epidemiology could inform targeted cancer risk-reduction strategies... - Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family RegistryAllison W Kurian
Stanford University School of Medicine, Department of Health Research and Policy, Stanford, CA 94305 5405, USA
Cancer Epidemiol Biomarkers Prev 18:1084-91. 2009..Two widely used models, BRCAPRO and BOADICEA, were developed using data from non-Hispanic Whites (NHW), but their accuracies have not been evaluated in other racial/ethnic populations... - Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2 mutations: findings from the Breast Cancer Family RegistryAllison W Kurian
Stanford University School of Medicine, Stanford, CA 94305, USA
J Clin Oncol 29:4505-9. 2011..We estimated breast cancer risks for noncarriers by using a population-based sample of patients with breast cancer and their female first-degree relatives (FDRs)... - The decline in breast cancer incidence: real or imaginary?Allison W Kurian
Stanford University School of Medicine, Stanford, CA 94305, USA
Curr Oncol Rep 11:21-8. 2009..However, significant controversy remains as to the timing, causes, generalizability, and longevity of this reported decline in incidence... - Feasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriersElizabeth A Schackmann
Departments of Medicine and of Health Research and Policy, Stanford University School of Medicine, Stanford, CA 94305 5405, USA
Fam Cancer 12:65-73. 2013..50 and 4.69, on a 1-5 scale). Patients and health care providers rated the decision tool highly on measures of usability and clinical relevance. These results will guide a larger study of the tool's impact on clinical decisions... - CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancerJeffrey A Norton
Department of Surgery, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94035, USA
Ann Surg 245:873-9. 2007.... - Asian ethnicity and breast cancer subtypes: a study from the California Cancer RegistryMelinda L Telli
Division of Medical Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
Breast Cancer Res Treat 127:471-8. 2011..Given the poor prognosis and high treatment costs of HER2-positive breast cancer, our results have implications for healthcare resource utilization, cancer biology, and clinical care... - Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell linesAshley A Powell
Department of Surgery, Stanford University School of Medicine, Stanford, California, USA
PLoS ONE 7:e33788. 2012..Here we demonstrate feasibility of performing high dimensional single CTC profiling, providing early insight into CTC heterogeneity and allowing comparisons to breast cancer cell lines widely used for drug discovery... - A young woman with bilateral breast cancer: identifying a genetic cause and implications for managementMonique A de Bruin
From the Departments of aMedicine, bGenetics, and cHealth Research and Policy, Stanford University School of Medicine, Stanford, California
J Natl Compr Canc Netw 11:512-7. 2013..Given the specialized counseling and testing needs of patients with Li-Fraumeni syndrome, and the implications for targeted screening strategies if a mutation is found, referral to a cancer genetics expert is strongly recommended... - Patterns and predictors of breast cancer chemotherapy use in Kaiser Permanente Northern California, 2004-2007Allison W Kurian
Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
Breast Cancer Res Treat 137:247-60. 2013..72, 95 % CI 1.02-2.90). In this equal-access healthcare system, chemotherapy use followed practice guidelines, but varied by race and socio-demographic factors. These findings may inform efforts to optimize quality in breast cancer care... - Histologic types of epithelial ovarian cancer: have they different risk factors?Allison W Kurian
Department of Medicine, Division of Oncology, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305 5820, USA
Gynecol Oncol 96:520-30. 2005..The goals of the current study were to characterize further the relation of histologic-specific ovarian cancer risks to reproductive and lifestyle attributes... - A carrier of both MEN1 and BRCA2 mutations: case report and review of the literaturePavandeep Ghataorhe
School of Medicine, Oxford University, South Parks Road, Oxford OX1 3PL, UK
Cancer Genet Cytogenet 179:89-92. 2007..To our knowledge, this is the first report of a patient with both MEN1 and BRCA2 mutations and with a personal history of hyperparathyroidism and pancreatic neuroendocrine tumors... - Magnetic resonance galactography: a feasibility study in women with prior atypical breast duct cytologyAllison W Kurian
Breast J 14:211-4. 2008